DK3127917T3 - Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof - Google Patents
Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof Download PDFInfo
- Publication number
- DK3127917T3 DK3127917T3 DK15773537.4T DK15773537T DK3127917T3 DK 3127917 T3 DK3127917 T3 DK 3127917T3 DK 15773537 T DK15773537 T DK 15773537T DK 3127917 T3 DK3127917 T3 DK 3127917T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- regulating
- procedure
- production
- sugar content
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140039307A KR101660580B1 (ko) | 2014-04-02 | 2014-04-02 | 항체의 당 함량 조절을 통한 항체의 제조 방법 |
| PCT/KR2015/003310 WO2015152658A1 (ko) | 2014-04-02 | 2015-04-02 | 항체의 당 함량 조절을 통한 항체의 제조 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3127917T3 true DK3127917T3 (da) | 2021-09-20 |
Family
ID=54240880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15773537.4T DK3127917T3 (da) | 2014-04-02 | 2015-04-02 | Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10808272B2 (da) |
| EP (1) | EP3127917B1 (da) |
| JP (1) | JP6389530B2 (da) |
| KR (1) | KR101660580B1 (da) |
| CN (1) | CN106459185B (da) |
| DK (1) | DK3127917T3 (da) |
| ES (1) | ES2893536T3 (da) |
| PT (1) | PT3127917T (da) |
| WO (1) | WO2015152658A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI734775B (zh) | 2016-04-26 | 2021-08-01 | 美商美國泰福生技股份有限公司 | 細胞培養基 |
| AU2019379858B2 (en) * | 2018-11-13 | 2024-01-04 | Janssen Biotech, Inc. | Control of trace metals during production of anti-CD38 antibodies |
| CN111321188B (zh) * | 2018-12-17 | 2024-10-29 | 嘉和生物药业有限公司 | 一种抗体糖型改造的配方、细胞培养方法以及在工业化生产中的应用 |
| JP7635137B2 (ja) | 2019-03-14 | 2025-02-25 | ヤンセン バイオテツク,インコーポレーテツド | 抗tnf抗体組成物を産生するための方法 |
| CN113840837A (zh) * | 2019-03-14 | 2021-12-24 | 詹森生物科技公司 | 用于产生抗tnf抗体组合物的方法 |
| CN114990049B (zh) * | 2022-04-26 | 2024-01-16 | 鼎康(武汉)生物医药有限公司 | 一种同时调节细胞表达产物的糖型和电荷异质性的方法 |
| CN116590371B (zh) * | 2023-07-13 | 2023-10-17 | 智享生物(苏州)有限公司 | 一种降低中华仓鼠卵巢细胞中抗体高甘露糖型的细胞培养方法 |
| WO2025137086A1 (en) * | 2023-12-20 | 2025-06-26 | Genentech, Inc. | Reducing alpha-gal |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08336389A (ja) * | 1995-06-14 | 1996-12-24 | Mitsui Toatsu Chem Inc | 糖蛋白質の糖鎖構造を制御する方法 |
| PT1176195E (pt) * | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| DE60120356T2 (de) * | 2000-02-08 | 2007-06-14 | Genentech, Inc., South San Francisco | Verbesserte galactosylierung von rekombinanten proteinen |
| EP1417577A4 (en) | 2001-08-14 | 2009-08-26 | Verisity Design Inc | SYSTEM AND METHOD FOR VCD ON DEMAND |
| US7439043B2 (en) * | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
| WO2005070962A1 (en) | 2004-01-21 | 2005-08-04 | Novozymes A/S | Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell |
| CN1918179A (zh) * | 2004-01-21 | 2007-02-21 | 诺和酶股份有限公司 | 在异核体真菌或真菌宿主细胞中产生单克隆抗体 |
| AU2011205185B2 (en) * | 2004-04-15 | 2013-05-09 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| ATE536373T1 (de) * | 2005-10-21 | 2011-12-15 | Genzyme Corp | Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität |
| SI1957630T2 (sl) * | 2005-12-08 | 2023-07-31 | Amgen Inc. | Izboljšana proizvodnja glikoproteinov z uporabo mangana |
| CA2677179C (en) * | 2007-01-31 | 2016-02-16 | Dow Global Technologies Inc. | Bacterial leader sequences for increased expression |
| NZ596283A (en) * | 2009-05-11 | 2013-08-30 | Pfenex Inc | Production of recombinant proteins utilizing non-antibiotic selection methods and the incorporation of non-natural amino acids therein |
| RU2604811C2 (ru) | 2010-05-27 | 2016-12-10 | Мерк Шарп Энд Домэ Корп. | Способ получения антител с улучшенными свойствами |
| EP2678030A4 (en) * | 2011-02-25 | 2015-02-18 | Merck Sharp & Dohme | PREPARATION OF N- AND O-SIALYLATED TNFRII-FC FUSION PROTEINS IN YEAST |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| KR20130057959A (ko) * | 2011-11-24 | 2013-06-03 | 한화케미칼 주식회사 | 항 her2 단일클론항체와 il-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물 |
| EP2809773B1 (en) * | 2012-01-30 | 2020-09-02 | Dr. Reddy's Laboratories Limited | Process of modulating man5 and/or afucosylation content of glycoprotein composition |
| KR101318498B1 (ko) * | 2012-03-08 | 2013-10-16 | 한화케미칼 주식회사 | 재조합 단백질의 생산성 향상을 위한 배양용 배지 첨가용 조성물 |
| CN103320388B (zh) * | 2012-03-20 | 2015-10-28 | 无锡药明康德生物技术股份有限公司 | 提高抗体表达量和改良糖基化水平的细胞培养方法 |
-
2014
- 2014-04-02 KR KR1020140039307A patent/KR101660580B1/ko active Active
-
2015
- 2015-04-02 CN CN201580023733.XA patent/CN106459185B/zh active Active
- 2015-04-02 PT PT15773537T patent/PT3127917T/pt unknown
- 2015-04-02 ES ES15773537T patent/ES2893536T3/es active Active
- 2015-04-02 EP EP15773537.4A patent/EP3127917B1/en active Active
- 2015-04-02 DK DK15773537.4T patent/DK3127917T3/da active
- 2015-04-02 WO PCT/KR2015/003310 patent/WO2015152658A1/ko not_active Ceased
- 2015-04-02 JP JP2016559960A patent/JP6389530B2/ja active Active
- 2015-04-02 US US15/300,710 patent/US10808272B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170107551A1 (en) | 2017-04-20 |
| CN106459185A (zh) | 2017-02-22 |
| JP6389530B2 (ja) | 2018-09-12 |
| EP3127917B1 (en) | 2021-09-01 |
| JP2017511137A (ja) | 2017-04-20 |
| ES2893536T3 (es) | 2022-02-09 |
| KR101660580B1 (ko) | 2016-09-28 |
| KR20150115066A (ko) | 2015-10-14 |
| US10808272B2 (en) | 2020-10-20 |
| EP3127917A4 (en) | 2017-04-26 |
| WO2015152658A1 (ko) | 2015-10-08 |
| EP3127917A1 (en) | 2017-02-08 |
| PT3127917T (pt) | 2021-10-15 |
| CN106459185B (zh) | 2021-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| IL251963A0 (en) | Anti-pd-1 antibodies | |
| DK3140393T3 (da) | Fremstillingsmetode for voksne leverstamceller | |
| LT3126395T (lt) | Daugiaspecifiniai antikūnai | |
| DK3183272T3 (da) | Asymmetriske multispecifikke antistoffer | |
| EP3356420C0 (en) | MULTI-SPECIFIC ANTIBODIES | |
| LT3161007T (lt) | Multispecifiniai antikūno konstruktai | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| HUE053857T2 (hu) | Anti-GITR antitestek és eljárások azok elõállítására | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3191517T3 (da) | Krydsreaktive siglec-antistoffer | |
| DK3164414T3 (da) | Antistoffer for IL-15 | |
| DK3253453T3 (da) | Fremgangsmåde til fremstilling af mælk med højt indbygget vitamin D3-indhold | |
| DK3237432T3 (da) | Proteinfremstilling | |
| DK3215517T3 (da) | Ether-funktionaliseret lignin til brændstofsproduktion | |
| DK3166904T3 (da) | Fremgangsmåde til fremstilling af betonelementer | |
| DK3218396T3 (da) | Fremgangsmåde til fremstilling af højaffinitets antistoffer | |
| DK3160266T3 (da) | Sukkererstatningssammensætning | |
| DK3147369T3 (da) | Fremgangsmåde til produktion af fibroinlignende protein | |
| HUE049170T2 (hu) | Eljárás szubsztituált cikloszerinek elõállítására | |
| PT3127917T (pt) | Método para preparar anticorpo através da regulação do conteúdo de açúcar do anticorpo | |
| DK3138903T3 (da) | Celler til produktion af humant antistof | |
| HUE047455T2 (hu) | HPA-1A elleni antitestek | |
| LT3178931T (lt) | Anti-orai1 antikūnas | |
| EP3160502B1 (en) | BI-SPECIFIC ANTIBODIES ANTI-IL4-IL13 |